Filing Flows › Comparisons › LGND vs EOLS
Ligand Pharmaceuticals vs Evolus: LGND and EOLS compared
Ligand Pharmaceuticals is the larger company: $78.7M of revenue in its latest quarter (Q3 2026) against $78.0M for Evolus (Q3 2026). Evolus is growing faster (+13% against -32% a year earlier). Evolus is more profitable, with an operating margin of -10.8% against -20.0%.
Where the money goes: LGND and EOLS
Ligand Pharmaceuticals (LGND) · Q3 2026
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
Evolus (EOLS) · Q3 2026
Evolus, Q3 2026: revenue $78.0M (+13% year over year), operating margin -10.8%, net loss $12.5M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Ligand Pharmaceuticals (LGND) | Evolus (EOLS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $78.7M | $78.0M |
| Revenue growth, Y/Y | -32% | +13% |
| Operating margin | -20.0% | -10.8% |
| Net earnings | −$28.5M | −$12.5M |
| Net margin | -36.2% | -16.1% |
| Operating cash flow | −$27.6M | −$1.9M |
Where the revenue comes from
Ligand Pharmaceuticals
- Revenue from intangible royalty assets: $47.2M (60%)
- Ojemda: $7.0M (9%)
- Other: $6.7M (8%)
- Capvaxive: $3.8M (5%)
Evolus
- Product revenue, net: $77.2M (99%)
- Service revenue: $741K (1%)
Questions
Which is bigger, Ligand Pharmaceuticals or Evolus?
Ligand Pharmaceuticals is the larger company: $78.7M of revenue in its latest quarter (Q3 2026) against $78.0M for Evolus (Q3 2026).
Is Ligand Pharmaceuticals or Evolus growing faster?
Evolus is growing faster (+13% against -32% a year earlier).
Which is more profitable, Ligand Pharmaceuticals or Evolus?
Evolus is more profitable, with an operating margin of -10.8% against -20.0%.
More: Ligand Pharmaceuticals earnings · how Ligand Pharmaceuticals makes money · Evolus earnings · how Evolus makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.